Cargando…

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination

Cytomegalovirus (CMV) is a globally ubiquitous pathogen with a seroprevalence of approximately 50% in the United Kingdom. CMV infection induces expansion of immunosenescent T cell and NK cell populations, with these cells demonstrating lower responsiveness to activation and reduced functionality upo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharpe, Hannah R., Provine, Nicholas M., Bowyer, Georgina S., Moreira Folegatti, Pedro, Belij-Rammerstorfer, Sandra, Flaxman, Amy, Makinson, Rebecca, Hill, Adrian V.S., Ewer, Katie J., Pollard, Andrew J., Klenerman, Paul, Gilbert, Sarah, Lambe, Teresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986084/ https://www.ncbi.nlm.nih.gov/pubmed/35192547 http://dx.doi.org/10.1172/jci.insight.154187

Ejemplares similares

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
por: Folegatti, Pedro M., et al.
Publicado: (2019)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
por: Marchevsky, Natalie Gabrielle, et al.
Publicado: (2022)

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
por: Folegatti, Pedro M, et al.
Publicado: (2020)

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
por: Ogbe, Ane, et al.
Publicado: (2022)

A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice
por: Silva-Cayetano, Alyssa, et al.
Publicado: (2021)

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
por: Flaxman, Amy, et al.
Publicado: (2021)

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials
por: Voysey, Merryn, et al.
Publicado: (2023)

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques
por: van Doremalen, Neeltje, et al.
Publicado: (2020)

Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model
por: van Doremalen, Neeltje, et al.
Publicado: (2022)

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
por: van Doremalen, Neeltje, et al.
Publicado: (2020)

A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
por: Folegatti, Pedro M., et al.
Publicado: (2021)

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
por: Berg, Adam, et al.
Publicado: (2021)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
por: Zhang, Cheng, et al.
Publicado: (2023)

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
por: Barrett, Jordan R., et al.
Publicado: (2021)

Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine
por: Watanabe, Yasunori, et al.
Publicado: (2021)

Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine
por: Watanabe, Yasunori, et al.
Publicado: (2021)

The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world
por: Sharpe, Hannah R., et al.
Publicado: (2020)

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19
por: Graham, Simon P., et al.
Publicado: (2020)

Reduced Ebola vaccine responses in CMV(+) young adults is associated with expansion of CD57(+)KLRG1(+) T cells
por: Bowyer, Georgina, et al.
Publicado: (2020)

HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV
por: Cargill, Tamsin, et al.
Publicado: (2023)

Inflammatory myositis after ChAdOx1 vaccination
por: Maramattom, Boby Varkey, et al.
Publicado: (2021)

ChAdOx1-S vaccine for prevention of COVID-19
Publicado: (2021)

ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants
por: van Doremalen, Neeltje, et al.
Publicado: (2022)

Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens
por: Antrobus, Richard D, et al.
Publicado: (2014)

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
por: Ramasamy, Maheshi N, et al.
Publicado: (2020)

ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
por: Lambe, Teresa, et al.
Publicado: (2021)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
por: Hermosilla, Eduardo, et al.
Publicado: (2022)

Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley Fever in adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
por: Jenkin, Daniel, et al.
Publicado: (2023)

Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels
por: Alharbi, Naif Khalaf, et al.
Publicado: (2019)

A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques
por: van Doremalen, Neeltje, et al.
Publicado: (2020)

Immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies
por: Thookhamme, Chayapa, et al.
Publicado: (2023)

Notice of addendum to Article reporting Oxford trial of ChAdOx1 nCoV-19 vaccine
por: Pollard, Andrew J
Publicado: (2020)

ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 – Authors' reply
por: Voysey, Merryn, et al.
Publicado: (2020)

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
por: Alharbi, Naif Khalaf, et al.
Publicado: (2017)

Postvaccinal Encephalitis after ChAdOx1 nCov‐19
por: Zuhorn, Frédéric, et al.
Publicado: (2021)

The COVID‐19 vaccine ChAdOx1‐S is not contaminated with sulfated glycosaminoglycans
por: Alban, Susanne, et al.
Publicado: (2022)

Prolonged febrile illness following first dose of ChAdOx1
por: Caruana Dingli, Michael, et al.
Publicado: (2023)

Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial
por: Bosaeed, Mohammad, et al.
Publicado: (2022)

Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment
por: Folegatti, Pedro M, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
por: Schmidt, Tina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tdf9lng4u95djq7u290b2jtero